Follow up after percutaneous MR-guided cryoablation of Small Renal Masses.

Recruiting

• Conditions: kidney cancer; Renal cell carcinoma; 10038430

• Registration Number: NL-OMON40801
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

>50 years of age;
At least one untreated T1a tumour of one kidney (tumour <= 4 cm in greatest dimension);
Signed IRB-approved informed consent form.

Exclusion Criteria

Relative contra indications for MR imaging (metal device/foreign bodies, claustrophobia);
Pregnancy or breast feeding;
Known hypersensitivity or HACA against Girentuximab.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Positive and negative predictive value of MRI and Indium-111-Girentuximab-DOTA<br /><br>SPECT 4-6 weeks after intervention.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Residual and recurrent free survival at 3 months follow up. </p><br>